Mirati Therapeutics | MRTX - Операционный доход



Операционный доход Изменить Дата
Agios Pharmaceuticals USD -110.02M 11.55M 2026-03
Alnylam Pharmaceuticals USD 112.6M 24.99M 2026-06
Amgen USD 3.83B 130M 2026-03
Astellas Pharma JPY 48.57B 85.97B 2026-03
AstraZeneca USD 3.16B 3.95B 2026-06
Bayer EUR 3.53B 2.42B 2026-03
BioCryst Pharmaceuticals USD 260.38M 230.79M 2025-12
Bristol-Myers Squibb USD 299M 3.07B 2026-06
Eisai JPY 24.73B 35.04B 2026-06
Eli Lilly USD 9.78B 792M 2026-03
Exelixis USD 251.34M 15.43M 2026-03
Gilead Sciences USD 2.68B 284M 2026-03
GlaxoSmithKline GBP 2.6B 312M 2026-06
Incyte USD 700.4M 376.22M 2026-06
Ionis Pharmaceuticals USD -102.29M 15.71M 2026-06
J&J USD 7.48B 860M 2026-06
Merck USD -1.88B 8.12B 2026-03
Moderna USD -815M 573M 2026-06
Nektar Therapeutics USD -38.26M 19.17M 2026-03
Novartis USD 4.75B 515M 2026-06
Pfizer USD 667M 4.32B 2026-06
Puma Biotechnology USD 22.08M 24.26M 2024-09
Roche Holding CHF 11.46B 1.91B 2026-06
Sarepta Therapeutics USD 358.43M 768.52M 2026-03
Takeda JPY 201.42B 215.04B 2026-06
Ultragenyx Pharmaceutical USD -216M 102M 2026-03